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Abstract During the last decade, several defects in self-
tolerance have been identiﬁed in multiple sclerosis. Dys-
function in central tolerance leads to the thymic output of
antigen-speciﬁc T cells with T cell receptor alterations
favouring autoimmune reactions. In addition, premature
thymic involution results in a reduced export of naı ¨ve
regulatory T cells, the fully suppressive clone. Alterations
in peripheral tolerance concern costimulatory molecules as
well as transcriptional and epigenetic mechanisms. Recent
data underline the key role of regulatory T cells that sup-
press Th1 and Th17 effector cell responses and whose
immunosuppressive activity is impaired in patients with
multiple sclerosis. Those recent observations suggest that a
defect in self-tolerance homeostasis might be the primary
mover of multiple sclerosis leading to subsequent immune
attacks, inﬂammation and neurodegeneration. The concept
of multiple sclerosis as a consequence of the failure of
central and peripheral tolerance mechanisms to maintain a
self-tolerance state, particularly of regulatory T cells, may
have therapeutic implications. Restoring normal thymic
output and suppressive functions of regulatory T cells
appears an appealing approach. Regulatory T cells suppress
the general local immune response via bystander effects
rather than through individual antigen-speciﬁc responses.
Interestingly, the beneﬁcial effects of currently approved
immunomodulators (interferons b and glatiramer acetate)
are associated with a restored regulatory T cell homeosta-
sis. However, the feedback regulation between Th1 and
Th17 effector cells and regulatory T cells is not so simple
and tolerogenic mechanisms also involve other regulatory
cells such as B cells, dendritic cells and CD56
bright natural
killer cells.
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Introduction
It is somewhat controversial as to whether multiple scle-
rosis (MS) is primarily an autoimmune disease. One of the
deﬁning features of autoimmune diseases is the failure of
the immune system to maintain self-tolerance against tis-
sue-speciﬁc antigens (TSAs). MS shares physiopathologic
mechanisms with other autoimmune disorders, notably a
genetic predisposition modulated by epigenetic and envi-
ronmental factors. Some of those risk factors are common
to several autoimmune diseases. It has even been suggested
that the interactions between genetic, epigenetic and
environmental risk factors might determine the clinical
phenotype of the autoimmune disorder [1]. The mecha-
nisms responsible for maintaining or restoring self-toler-
ance have been the focus of signiﬁcant attention during the
last decade. In this review, we will concentrate on recent
data concerning the breaches in central and peripheral
tolerance in MS as well as their potential therapeutic
implications.
Central tolerance
Central tolerance results from the elimination of autore-
active cells in the thymus for T cells and bone marrow for
B cells, leading to the generation of mature T and B cell
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playing tolerance to self-antigens.
Positive selection tests the ability of the T cell receptor
(TCR) to signal in response to self-peptide-major histo-
compatibility (MHC) complexes displayed by cortical
thymic epithelial cells (cTECs). Thymocytes-expressing
TCRs with very low or no afﬁnity for MHC complexes, die
by neglect. Surviving thymocytes pass subsequently in the
thymic medulla where they encounter medullary thymic
epithelial cells (mTEC) that express TSAs [2]. Negative
selection eliminates thymocytes with a strong signal in
response to self-MHC-peptide via active apoptosis.
Negative selection is mainly mediated by the autoim-
mune regulator (Aire) gene encoding the Aire protein [3]
that modulates the intracellular expression of TSAs.
Recently, Aire has also been identiﬁed in peripheral lym-
phoid organs where it regulates expression of TSAs distinct
from those expressed in the thymus [4]. Interestingly,
transplantation of Aire-encoding bone marrow cells in
mice attenuates the development of MOG-induced exper-
imental autoimmune encephalomyelitis (EAE) [5].
Protection against autoimmunity for a speciﬁc organ
requires a minimal expression threshold level of the con-
cerned TSA. Thymocytes that receive TCR signals just
below the threshold for negative selection can undergo
a program of differentiation to become natural CD4
?
CD25
?Foxp3
? regulatory T cells (nTreg) [6]. Importantly,
both mTECs and dendritic cells (DC) cells contribute to
negative selection of naı ¨ve T cells and generation of
nTregs [7].
The presence of autoreactive T cells in the periphery in
MS patients and in healthy controls (HC) demonstrates that
central tolerance is not completely efﬁcient. Escape from
negative selection may result from TCR dysfunction or
from a weak binding of the self-peptide to the MHC II,
which destabilizes the complex with TCR.
Alterations in the crystal structure of TCRs from two
MS patients have been identiﬁed [8]. Both TCRs engage
peptide–MHC complex through altered docking modes.
The TCR is centred not over the central portion of the
MBP–MHC complex, but over its N-terminal portion.
Consequently, the overall stability of the TCR–MBP–MHC
complex is markedly reduced, its afﬁnity is suboptimal and
the thymocytes avoid negative selection. Recently, another
structural analysis of the TCR from a MS patient has been
reported [9]. In this patient, the TCR engaged the MBP–
MHC complex in a canonical mode and had a strong
afﬁnity for this complex, but the binding of MBP to HLA-
DR4 was unusually weak and permitted escape from neg-
ative selection.
Another aspect of thymic dysfunction in MS is its
inability to maintain T cell homeostasis. A defect in global
naı ¨ve T cell thymic output, as demonstrated by a marker of
newly exported naı ¨ve T cells (TCR excision circles-
TREC), has been demonstrated in young relapsing–remit-
ting (RR) MS patients [10]. Further studies showed that
TREC numbers in MS patients were lower than those in
age-matched HC suggesting a premature thymic involution
in MS [11, 12]. TRECs decrease signiﬁcantly with
increasing age in HC whereas no age-associated TREC
reduction is observed in MS.
This particular thymic dysfunction in MS was conﬁrmed
with CD31
high, a marker for recent, immature CD4 thymic
emigrant (RTEs) naı ¨ve T cells [13]. Similar thymic alter-
ations, even more pronounced, have been reported in
patients with primary progressive (PP) MS. Those obser-
vations suggest a low thymic export early in life and likely
before disease onset [14].
Peripheral tolerance
Peripheral tolerance is regulated by complex T cell
intrinsic mechanisms (costimulatory signalling, transcrip-
tional and epigenetic mechanisms) as well as by extrinsic
mechanisms (regulatory T cells).
Intrinsic mechanisms
Costimulatory molecules
In addition to the TCR–peptide–MHC complex, costimu-
latory signals are required to activate T cells. In the
absence of these signals, T cells become ‘‘anergic’’ and
induce self-tolerance.
CD28 binds to B7.1 (CD80) and B7.2 (CD86). CD4
?
CD28
null cells have been identiﬁed in peripheral blood of
MS patients. Less sensitive to regulatory mechanisms, they
have indirect pathogenic capacities [15] and were found to
produce higher levels of IFNc [16].
ICOS (inducible costimulator protein) binds to B7H and
modulates Th1/Th2 cytokine production. Genetic analyses
show that the frequency of ICOS gene AA homozygosity is
signiﬁcantly lower in patients with RR MS than in HC.
Patients expressing the AA homozygosity have lower
relapse rate and disability score [17].
CD40 plays an ambivalent role in MS pathogenesis [18].
Engagement of CD40 with its ligand (CD40-L = CD154)
in mTECs can contribute to the development of central
tolerance. On the other hand, CD40 promotes T cell dif-
ferentiation to Th17 cells. In MS patient brain lesions,
CD40-L is expressed on activated CD4 cells in secondary
progressive (SP), but not in RR MS or in HC [19]. Its
higher expression on peripheral lymphocytes in SP patients
might be associated with the shift from RR to SP MS
[20, 21].
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the same receptors as CD28 but has a negative regulatory
function. CTLA-4 expression is lower in SP than in RR MS
[22] and a low percentage of cells expressing CTLA-4
seems associated to earlier transition to the SP stage [23].
PD-1 (programmed death pathway 1) is expressed by
activated T cells. A strong upregulation of its ligand PD-L1
(also known as B7H1) has been observed in MS lesions and
identiﬁed as a down-regulator of T cell responses [24]. A
signiﬁcant association of a PD-1 polymorphism with the
progressive form of MS has been reported [25].
4-1BB (CD137) expression is downregulated on both
Tregs and DC in MS [26, 27]. The soluble form of its
ligand (s4-1BBL) is consistently elevated in plasma [28]
and cerebrospinal ﬂuid (CSF) [29] of MS patients. Those
observations suggest that altered 4-1BB/s4-1BBL interac-
tions may be involved in the impaired regulatory function
of Treg and plasmacytoid DC in MS patients.
CD58 mRNA expression is signiﬁcantly increased in
MS patients during relapses. Its protective effect seems
partly due to an enhancement of Foxp3 expression in Tregs
[30].
Transcriptional mechanisms
Foxp3, a transcriptional factor responsible for the differ-
entiation of CD4 and CD8 cells in the regulatory pheno-
type, is impaired in RR MS [31]. Altered apoptotic
mechanisms have been observed in RR MS [32] and
microarray analyses have identiﬁed a dysfunction of
nuclear receptor family members in the pre-disease state of
MS [33]. Both mRNA and protein levels of Casitas B cell
lymphoma-b (Cbl-b), a negative regulator of T cell acti-
vation, inversely correlate with relapses and are signiﬁ-
cantly decreased in MS patients particularly during
exacerbations [34].
Epigenetic mechanisms
Several observations suggest that histone modiﬁcations are
involved in programming T cell tolerance. Tolerant CD4
and CD8 T cells exhibit threefold more DNA methylation
within IL-2 promoter compared with activated cells [35].
Epigenetic mechanisms control the fate of Tregs by
inducing and stabilizing Foxp3 expression [36].
Extrinsic mechanisms
This review will be limited to regulatory T cells, excluding
regulatory B cells, tolerogenic DC and CD56
bright NK cells.
Suppressive activity of T cells received little attention till
the observation that self-tolerance was maintained by
activated CD4 cells expressing IL-2 receptor (CD25) in
mice [37] and in humans [38]. Progress related to pheno-
type and function of T cell subsets made possible the
identiﬁcation of CD8 regulatory T cells in rats [39] and in
MS patients [40].
CD4
?CD25
?Foxp3 regulatory T cells (Tregs)
CD4
?CD25
?Foxp3 cells represent a heterogeneous popu-
lation and the lack of a speciﬁc marker for the Treg cell
phenotype likely explains some contrasting observations
concerning their frequency and function.
In addition to CD25, Foxp3 is a master regulatory gene
for their cell-lineage differentiation and determines their
commitment in the maintenance of immune homeostasis
and self-tolerance. The Foxp3 protein expression at the
cellular level correlates with the suppressive activity of
Tregs [31].
Natural Tregs are functionally mature antigens primed
in the thymus before encountering antigens in the periphery
and competent to prevent autoimmunity [41]. They migrate
to peripheral secondary lymphoid organs. Within lymph
nodes, they interact with DC and block their capacity to
prime naı ¨ve CD4 and their subsequent differentiation into
autoreactive self-speciﬁc T cells [42]. They exert their
suppressive activity by cell-to-cell contact.
According to speciﬁc modes of antigen stimulation in a
particular milieu, Foxp3 can convert naı ¨ve CD4 T cells into
the inducible regulatory phenotype (iTregs) functionally
similar to nTregs [43]. They only differ in their epigenetic
regulation of Foxp3 [44]. Their suppressive effects do not
require cell-to-cell contact but are mainly mediated by
cytokines such as IL-10 and IL-35 as well as by TGFb [45].
Importantly, uncommitted nTregs retain developmental
plasticity and both fully differentiated iTregs and nTregs
can be reprogrammed by IL-6 towards the Th17 lineage
[46–48].
The nature of many suppressive mechanisms exerted by
Tregs remains elusive and it remains unclear whether they
use the same or different mechanisms to control different
cell types. Treg activation requires antigen speciﬁc recog-
nition but Treg suppression is non-speciﬁc and is exerted
via bystander effects.
Observations concerning the frequency of nTregs in the
periphery between MS patients and HC are contradictory.
No differences [49–52] as well as an increase in their
numbers [53, 54] has been reported.
In contrast, the numbers of Tregs are consistently found
increased in the CSF of MS patients compared with HC [52,
55]. Of note that Tregs cells are scarce in MS brain lesions
[56] whereas in EAE, they proliferate into the CNS [57].
A signiﬁcant defect in the suppressive function of
nTregs was ﬁrst demonstrated in RR MS [49] and was
further conﬁrmed by a lower inhibitory effect of Tregs
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induced by recombinant MOG and allogenic stimuli [51].
An altered suppressor function of Tregs associated with a
low mRNA expression of Foxp3 was observed in RR,
mainly in the early phase of the disease, but not in patients
with SP MS who have normal suppressive function and
normal Foxp3 expression [31]. The defect in immunosup-
pressive activity actually lies in the Treg function as CD4
responder cells were not refractory to suppression [49, 51].
A genome-wide expression analysis in Tregs from MS
patients shows that 23 miRNAs are differentially expressed
compared with HC. Down-regulation of TGFb pathways
by miRNAs might result in altered Treg function [58].
Other functional surface markers that are components of
the suppressive mechanisms of Tregs have also been
investigated. A subset of Tregs bearing the CD39 and
CD73 markers seems more speciﬁcally involved in regu-
lating IL-17 toxicity suppression [59]. Both CD39 and
CD73 are potent immunosuppressive molecules. Patients
with RR MS have markedly reduced numbers of CD39 in
the blood [60]. Their suppressive activity is less effective
in RR compared with SP MS.
Tregs express low levels of CD127 (IL-7 receptor a
chain), a marker of activation that negatively correlates
with Foxp3 expression and suppressive activity. When
CD4
?CD25
?CD127
low Tregs were segregated in naı ¨ve and
memory T cells, the suppressive activity of naı ¨ve Tregs
after CD3 costimulation was found reduced in both RR and
SP MS. Of note that memory Treg numbers and function
were restored during the progressive phase [61]. More
recently mature and non-mature CD127
low Tregs were
found defective in suppressive activity after CD2 costi-
mulation in patients with RR MS [62]. In contrast, using a
more stringent threshold for CD25 expression and after
elimination of CD127
high Tregs, remaining Tregs had
normal function in RR MS patients [63]. This underlines
the difﬁculty to accurately identify Tregs in the absence of
a speciﬁc marker.
In non-inﬂammatory conditions, Tregs participate to
immunosurveillance. They express the CCR6 adhesion
molecule and in HC exhibit a stronger migratory response
to CCL20 than Th17 cells. In RR MS, their migratory
capacities are signiﬁcantly impaired, facilitating the initi-
ation of inﬂammation by Th17 cells [64].
An increase in percentage of CD4
?CD25
? correlating
with disease activity was ﬁrst reported in 2000 [65]. An
evaluation of Treg markers in stable and relapsing patients
has been recently performed with usual markers of Tregs
(CD25 and Foxp3) as well as ‘‘functional’’ markers (CD39/
CD73, CTLA-4 and glucocorticoid-induced TNF-GITR)
that are supposed to ﬂuctuate with disease evolution [66].
In patients longitudinally followed for 1 year, whatever the
expressed markers, strikingly reduced numbers of Tregs
were found in stable patients compared with HC. In con-
trast, all Treg subset numbers and suppressive function
were signiﬁcantly increased during relapses.
CD8
?CD25
?Foxp3
? (CD8 Tregs)
After a decade of focusing on CD4 Tregs, CD8 Tregs have
recently gained interest [67]. Like their CD4 counterpart,
CD8 Tregs are a heterogeneous population. There is no
speciﬁc marker of CD8 Tregs. Functional markers cate-
gorize them as natural (from thymic output) or induced
(from the post-thymic cell pool). CD8 Treg cells can be
induced from CD8
?CD25
- T cells by continuous antigen
stimulation. Several studies have shown that CD8 Tregs
recognize and lyse activated myelin-speciﬁc CD4 cells
[68]. This cytotoxic response is decreased in peripheral
blood and in the CSF in MS patients during exacerbations
[40, 69]. Apart from exacerbation periods, numbers and
suppressive function of CD8 Tregs do not seem to differ
between MS patients and HC [70].
Other regulatory T cells
Tr1 is a regulatory T cell phenotype characterized by a
high amount of IL-10 secretion. A marked defect in the
induction of Tr1 cells has been observed in patients with
MS compared with HC [71].
Th3 regulatory T cells producing TGFb are generated in
MSpatientsafteroraladministrationofmyelinantigens[72].
HLA-G regulatory T cells are CD25
- Foxp3
- cells
exerting their suppressive activity independently of IL-10
and IFNb [73]. A correlation with clinical and MRI disease
activity for sHLA-G CSF levels [74] but not for serum
levels [75] has been reported.
TCR-ab CD4
-CD8
- double negative T cells (DN-T)
highly differ from nTreg [76]. They do not express the
marker Foxp3 and exert their suppressive activity by mod-
ulating TCR signalling. The immunosuppressive properties
of DN-T have not been explored in EAE or MS so far.
Discussion
Multiple sclerosis is characterized by three closely inter-
mingled, basic pathomechanisms: autoimmune reactions,
non-resolving inﬂammation and neurodegeneration. Non-
resolving inﬂammation can initiate autoimmunity and
conversely autoimmunity can initiate inﬂammation. Both
immune reactions and inﬂammation can mediate neuro-
degeneration but which comes ﬁrst in MS remains an open
question.
Several defects in self-tolerance have been recently
identiﬁed in MS. Dysfunction in central tolerance leads to
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alterations favouring autoimmune reactions [8, 9]. More-
over premature thymic involution in MS results in a
reduced export of RTE naı ¨ve Treg, the fully suppressive
Treg clone [13]. The low thymic output of naı ¨ve Tregs
cannot maintain a functional homeostasis despite a stable
cell count of the total Treg population due to an increased
proliferation of less immunosuppressive memory Tregs.
Peripheral Treg cell development alone is not sufﬁcient to
establish self-tolerance and generation of Treg cells in the
thymus is crucial for maintaining immune homeostasis.
Some observations argue ﬁrmly for the presence of those
self-tolerance defects before the outset of the disease
[14, 33].
Dysfunctions of peripheral tolerance concern costimu-
latory molecules as well as transcriptional and epigenetic
mechanisms. Recent data underline the key role of Tregs
that suppress Th1 and Th17 effector cell (Teff) responses.
Teff are the main source of IL-2 and, on the other hand, IL-
2 is essential for Treg expansion. It has been proposed that
this interdependence constitutes a feedback mechanism,
impaired in MS patients, indexing the number of Treg cells
to the number of Teff cells and adapting their respective
proportions to maintain a Teff/Treg equilibrium and
immune system homeostasis [77].
Those recent observations suggest that a defect in physio-
logicalmechanisms,whosepurposeistopreventortoregulate
and terminate a potential response to circulating myelin spe-
ciﬁc T cells, might be the primary cause of MS leading to
immune reactions and subsequent inﬂammation. In line with
this idea, the genetic predisposition of MS notably concerns
mechanisms regulating autoimmune mediated inﬂammatory
responses[78]anddeterminingindividual’sinherentabilityto
resist autoimmune induction [79].
No major differences between circulating myelin speciﬁc
cells in the blood of MS patients and healthy controls have
been observed. However, the last mentioned do not develop
MS. Furthermore, if a local tissue injury in the CNS (e.g.
viral infection) leading to myelin destruction was the prime
mover of autoimmune reactions and subsequent inﬂamma-
tion it seems difﬁcult to understand why patients with stroke
or brain trauma do not develop progressive demyelinating
lesions. In those patients indeed, myelin destruction leaks
brain speciﬁc antigens that are exposed to immune reactive
cells and can be measured in the CSF [80]. Even if the
conditionsarepresent,autoimmunereactionsdonotdevelop
intheCNS.Itseemsthereforethat,incontrasttoMSpatients
whose regulatory mechanisms are compromised, patients
with a healthy immune system are able to control and ter-
minate inﬂammatory damages when myelin speciﬁc T cells
accidentally recognize exposed brain antigens (CNS injury-
induced immunodepression syndrome, CIDS). Also note-
worthy is the fact that Tregs counteract production of
proinﬂammatory cytokines, lymphocyte inﬁltration and
microglial activation via IL-10 production in experimental
acute stroke [81].
The concept of MS as a consequence of the failure of
central and peripheral tolerance mechanisms, particularly
of Tregs, to maintain a self-tolerance state may have
therapeutic implications. Restoring normal Treg function
appears an appealing approach. Indeed, Tregs globally
suppress local responses via bystander effects rather than
through a speciﬁc response for the antigen recognized
by Tregs. Of particular interest are the observations that
the beneﬁcial effects of currently approved immunomod-
ulators are associated with a restored Treg homeostasis.
Administration of GA stimulates the differentiation of
CD4
?CD25
- into iTregs [82] and activates the thymo-
poietic pathways [83] restoring the balance between naı ¨ve
Tregs and memory Tregs [84]. The same holds true for
IFNb and INFa treatments that restore and/or increase Treg
populations and function directly or via DC modulation
[54, 55, 85–87].
Numerous approaches in experimental models of auto-
immune diseases are currently investigated to boost Tregs
numbers and function. Adoptive cell transfer of patient-
speciﬁc Tregs requires overcoming technical problems and
would be quite expensive. Anti-CD3 therapy causes a dra-
matic expansion of a speciﬁc and strongly immunosuppres-
sive Treg population restricted to peripheral ‘‘niches’’ in
lymphoid organ [88]. Short-term low-dose IL-2 treatment
preferentiallytargetsTregsratherthanTeffcellsandinduces
a long-term protection in experimental type 1 diabetes [89].
Treg cell epitopes (tregitopes) are peptides expressed in the
Fc and Fab domains of IgGs. They speciﬁcally induce and
expand iTregs and generate antigen-speciﬁc adaptive toler-
ance to MOG epitopes in vivo [90]. We must not forget that
the translation of experimental beneﬁt into therapies for
human patients can lead to unexpected adverse outcomes.
Selective targeting of Tregs with superagonistic anti-CD28
antibodies induces a marked Treg expansion and protects
from EAE [91]. Well tolerated in animals, its infusion into
healthy people in a phase I trial provoked a life-threatening
cytokine storm [92].
Conclusion
During the last decade, numerous observations have
underscored the failure to maintain self-tolerance as an
important pathomechanism in MS development and evo-
lution. Alterations of regulatory T cells as early as from
their generation in the thymus strongly support the concept
of MS as an autoimmune disease. MS seems thus to be
primarily the result of the failure to sustain protective
immunity [79]. In MS, Tregs cannot prevent circulating
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inﬂammatory reactions. This Treg impairment gives rise to
non-resolving inﬂammation during which acute and
chronic inﬂammation may coexist. Inﬂammation then ini-
tiates a degenerative cascade and tissue injury. At the
moment,ourcurrenttreatmentscanonlytargetinﬂammatory
processes.Ourrecentunderstandingofimmunemechanisms
initiating inﬂammatory and degenerative cascades holds the
potential to restore the altered self-tolerance associated
with MS pathogenesis. It should be noted, however, that the
Teff/Treg homeostasis concept is not so simple and that
regulatory mechanisms involve other tolerogenic cells such
as B, DC and CD56
bright NK cells.
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